SciELO - Scientific Electronic Library Online

vol.18 número4Eficacia de un nuevo stent de nitinol fabricado localmente, en el tratamiento de la obstrucción maligna esofágica índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Revista Colombiana de Gastroenterologia

versão impressa ISSN 0120-9957


Terapia cuádruple con furazolidona como tratamiento de rescate para la infección por Helicobacter pylori. Rev Col Gastroenterol [online]. 2003, vol.18, n.4, pp.222-227. ISSN 0120-9957.

Therapeutic failures are often seen in the treatment of H. Pylori (HP) infection; different studies show that this can happen in 10 to 20% of cases. The principal factors involved in the lack of success are: primary resistance to antibiotics and the non compliance to treatment. The objective of the present work is to evaluate the efficacy and tolerance of a quadruple formulation with furazolidone in patients with persistent infection after several trials to eradicate HP. Materials and methods. This is a prospective work done with adult patients aged 18 to 75 years, to whom a persistent HP infection was found at least six weeks after one or several treatments for its eradication. All of them received oral treatment with the following scheme during 10 days: omeprazole, 20 mg fasting and before supper, tetracycline chlorhydrate 500 mg four times a day, amoxicillin, 500 mg four times a day, and furazolidone, 100 mg four times a day (OTAF 10). The outcome variable was the eradication of HP: absence of the infection proven by the three methods used: urea respiratory test, histopathology and fast urease test. This variable was analysed on an "intention to treat" basis. Patients taking at least 80% of each drug were included in the "per protocol" analysis. The eradication rate was expressed as a percentage with confidence intervals of 95% Results. Ninety patients were studied, 62% women. Age average was 44,3 ± 12.9 years. HP was eradicated as treatment intention in 81.1%, CI 95%, 71.2 to 83.3%; and 83.9% by protocol, CI 95%, 73.7 to 90%. Adverse side effects were present in 20% of patients. Only three patients withdrew because of headaches, diarrhea and rash respectively. Conclusion: OTAF 10 is an acceptable strategy as an empirical rescue treatment after treatment failures for its 80% efficacy, low cost, tolerance and safety.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons